Abstract: TH-PO1048
Health Care Resource Use and Costs Among Patients with CKD by Stage
Session Information
- CKD: Epidemiology, Risk Factors, and Other Conditions
November 06, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention
Authors
- Lee, Lydia Yejin, Boehringer Ingelheim Corp USA, Ridgefield, Connecticut, United States
- Gronroos, Noelle N, Optum Inc, Eden Prairie, Minnesota, United States
- Bengtson, Lindsay GS, Boehringer Ingelheim Corp USA, Ridgefield, Connecticut, United States
Background
Chronic kidney disease (CKD) is linked to economic burden. This study evaluated healthcare resource utilization (HCRU) and costs for patients with CKD.
Methods
This descriptive study utilized the Optum Research Database from December 2021 to December 2023, including adults with at least two CKD diagnoses and one CKD medication fill. Index date was defined as a medication fill for CKD treatment, and variables were measured in the 12-month baseline period. Patient characteristics and all-cause and CKD-related HCRU and costs were measured overall and stratified by CKD stage and health plan type (commercial [COM] or Medicare Advantage [MA]).
Results
A total of 29,635 COM and 373,409 MA patients met the study criteria; 38% of COM patients and 56% of MA patients were female, 58% of COM and 71% of MA patients had stage 3 CKD, and for both COM and MA ~64% were non-Hispanic White and ~16% were non-Hispanic Black. In both COM and MA cohorts, baseline HCRU and costs were numerically higher in stages 3 and 4 compared to stages 1 and 2, except for MA pharmacy fills/costs, which had a U-shaped relationship with highest cost/utilization in stages 1 and 4 (Table 1).
Conclusion
This study underscores the increasing HCRU, and costs associated with advancing CKD stages and varying economic burden of CKD by insurer type. These findings highlight the need for strategies to manage patients with CKD in earlier stages to prevent greater costs in later stages.
All-Cause and CKD-Related Costs by CKD Stage and Cohort
| Commercial | Medicare Advantage | |||||||
| Stage 1 | Stage 2 | Stage 3 | Stage 4 | Stage 1 | Stage 2 | Stage 3 | Stage 4 | |
| All-Cause | ||||||||
| Ambulatory Costs | 9,170 | 9,162 | 12,290 | 13,117 | 6,518 | 6,222 | 6,657 | 7,314 |
| Emergency Department Costs | 955 | 805 | 995 | 1,053 | 863 | 920 | 1,030 | 1,237 |
| Inpatient Stay Costs | 5,886 | 5,618 | 7,869 | 7,892 | 4,776 | 4,592 | 5,157 | 6,537 |
| Pharmacy Costs | 8,108 | 8,287 | 9,672 | 10,996 | 7,300 | 6,336 | 6,761 | 9,100 |
| CKD-Related | ||||||||
| Ambulatory Costs | 186 | 192 | 322 | 673 | 163 | 190 | 267 | 590 |
| Emergency Department Costs | 0.00 | 0.01 | 0.01 | 0.05 | 5 | 7 | 17 | 49 |
| Inpatient Stay Costs | 0.01 | 0.01 | 0.04 | 0.08 | 342 | 476 | 947 | 2,171 |
| Pharmacy Costs | 6.5 | 6.2 | 6.3 | 6.3 | 1,091 | 831 | 846 | 1,215 |
Funding
- Commercial Support – Boehringer Ingelheim